Matchpoint Unveils $1 Billion Agreement with Novartis

Ropes & Gray has successfully advised Matchpoint Therapeutics in finalizing an exclusive option and license agreement with pharmaceutical giant Novartis. Announced on July 24, this significant deal focuses on the development and commercialization of oral covalent inhibitors, which target specific transcription factors linked to a variety of inflammatory diseases. Matchpoint will utilize its proprietary Advanced Covalent Exploration platform to advance its preclinical program to development candidate selection. In exchange, Matchpoint will benefit from an upfront payment and research funding of up to $60 million from Novartis. Should Novartis proceed to exclusively license the program, it will gain global rights to any resulting products, while Matchpoint stands to earn up to $1 billion through various milestones and royalties. The advisory team from Ropes & Gray, led by key partners in life sciences licensing, tax, and litigation, played a crucial role in structuring this agreement.